Skip navigation
Skip navigation

Policy challenges of nanomedicine for Australia's PBS

Faunce, Thomas


All major pharmaceutical companies are currently investing significantly in the development of medicines with a nanotechnology component. Such research promises therapeutic drugs with greater efficacy and a wider range of clinical indications. Nanomedicines are just beginning to enter drug regulatory processes, but within a few decades could comprise a dominant group within the class of innovative pharmaceuticals. The current thinking of government safety and cost-effectiveness regulators...[Show more]

CollectionsANU Research Publications
Date published: 2009
Type: Journal article
Source: Australian Health Review
DOI: 10.1071/AH090258


File Description SizeFormat Image
01_Faunce_Policy_challenges_of_2009.pdf217.31 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  20 July 2017/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator